Program
Liposomal Bupivacaine
Also written as “EXPAREL”, “bupivacaine liposome injectable suspension” and “Exparel”.
Its studies are mostly in Pain, Postoperative · Pain · Bunion · Intestinal Obstruction · Hallux Valgus, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pacira BioSciences | 361 open or running | phase 4since Oct 23, 2011 | Oct 23, 2011 | Jan 2027phase 1 · NCT06271265 |
| Heron Therapeutics | 10 open or running | phase 4since Sep 23, 2019 | Sep 23, 2019 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | none ahead |
| Nuance Pharma (shanghai) | 10 open or running | phase 1since Nov 5, 2019 | Nov 5, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Oct 23, 2011.
- Sep 19, 2018Phase 4 study in AgnosiaPacira BioSciences · NCT03853694 · 167 enrolled · United States
- Sep 20, 2018Phase 3 study in Postoperative Pain ManagementPacira BioSciences · NCT03682302 · 98 enrolled · United States
- Apr 19, 2019Phase 4 study in Postoperative Pain ManagementPacira BioSciences · NCT03927911 · 65 enrolled · United States
- May 14, 2019Phase 4 study in Hip FracturesPacira BioSciences · NCT03955458 · United States
- May 15, 2019Phase 3 study in BunionPacira BioSciences · NCT03954639
- Jun 25, 2019Phase 1 study in BunionPacira BioSciences · NCT04002089 · 45 enrolled · United States
- Sep 23, 2019Heron Therapeutics’ first study: phase 4 study in AgnosiaNew to Heron TherapeuticsHeron Therapeutics · NCT04102267 · 32 enrolled · United States
- Nov 5, 2019Nuance Pharma (shanghai)’s first study: phase 1 study in Healthy SubjectsNew to Nuance Pharma (shanghai)Nuance Pharma (shanghai) · NCT04158102 · 20 enrolled · China
- Nov 18, 2019Phase 1 study in HealthyPacira BioSciences · NCT04173611 · 20 enrolled · United States
- Feb 29, 2020Phase 1 study in Breast AugmentationPacira BioSciences · NCT04293809 · 30 enrolled · United States
- Aug 4, 2020Phase 3 study in BunionPacira BioSciences · NCT04518462 · 121 enrolled · United States
- Nov 15, 20212 phase 3 studiesPacira BioSciences · NCT05157841, NCT05139030
- Jan 18, 2024Phase 1 study in Pain, PostoperativePacira BioSciences · NCT06271265 · 48 planned · United States
- Dec 1, 2025Jiangsu HengRui Medicine’s first study: phase 1 study in Postoperative Local AnalgesiaNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07279155 · 36 enrolled · China
Ahead
- Jan 2027Primary completion: phase 1 study in Pain, PostoperativePacira BioSciences · NCT06271265
TargetBeta
“Sodium channel protein type IV alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on SCN4A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Ranolazinerule | Gilead Sciences | phase 4 | 26 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07279155Postoperative Local Analgesia · China | 1 | Completed | Jiangsu HengRui Medicine | Jul 21, 2025 | 36 |
| NCT06271265Pain, Postoperative · United States | 1 | Recruiting | Pacira BioSciences | Jan 2027 | 48 |
| NCT05157841Hallux Valgus · United States | 3 | Completed | Pacira BioSciences | Aug 17, 2022 | 185 |
| NCT05139030Osteoarthritis, Knee · United States | 3 | Completed | Pacira BioSciences | Jul 11, 2022 | 167 |
| NCT04518462Bunion · United States | 3 | Completed | Pacira BioSciences | Apr 5, 2021 | 121 |
| NCT04293809Breast Augmentation · United States | 1 | Completed | Pacira BioSciences | Jan 15, 2020 | 30 |
| NCT04173611Healthy · United States | 1 | Terminated | Pacira BioSciences | Dec 7, 2020 | 20 |
| NCT04158102Healthy Subjects · China | 1 | Completed | Nuance Pharma (shanghai) | Dec 17, 2019 | 20 |
| NCT04102267Agnosia · United States | 4 | Completed | Heron Therapeutics | Sep 3, 2018 | 32 |
| NCT04002089Bunion · United States | 1 | Completed | Pacira BioSciences | Dec 2, 2019 | 45 |
| NCT03954639Bunion | 3 | Withdrawn | Pacira BioSciences | Sep 2020 | 0 |
| NCT03955458Hip Fractures · United States | 4 | Withdrawn | Pacira BioSciences | May 2020 | 0 |
| NCT03927911Postoperative Pain Management · United States | 4 | Terminated | Pacira BioSciences | Aug 4, 2020 | 65 |
| NCT03682302Postoperative Pain Management · United States | 3 | Completed | Pacira BioSciences | Aug 30, 2019 | 98 |
| NCT03853694Agnosia · United States | 4 | Completed | Pacira BioSciences | Jan 9, 2020 | 167 |
| NCT03485014Postoperative Pain Management · United States | 1 | Completed | Pacira BioSciences | Feb 12, 2019 | 15 |
| NCT03428984Postoperative Pain Management · United States | 1 | Terminated | Pacira BioSciences | Sep 28, 2018 | 5 |
| NCT03176459Agnosia · United States | 4 | Completed | Pacira BioSciences | Nov 20, 2018 | 186 |
| NCT02985762Agnosia · United States | 1 | Completed | Pacira BioSciences | Sep 2017 | 15 |
| NCT03015961Postoperative Pain Management · United States | 4 | Terminated | Pacira BioSciences | Oct 30, 2017 | 38 |
| NCT02713490Pain · United States | 4 | Completed | Pacira BioSciences | Feb 8, 2017 | 140 |
| NCT02713230Pain · United States, Belgium, Denmark | 3 | Completed | Pacira BioSciences | Jul 7, 2017 | 156 |
| NCT02713178Pain · United States, Belgium, Denmark | 3 | Completed | Pacira BioSciences | Jun 30, 2017 | 232 |
| NCT02353754Pain · United States | 4 | Terminated | Pacira BioSciences | Jun 2015 | 12 |
| NCT02255500Pain · United States | 4 | Completed | Pacira BioSciences | Mar 2015 | 23 |
| NCT02210247Healthy Volunteers · United States | 1 | Completed | Pacira BioSciences | Sep 2014 | 60 |
| NCT02199574Pain · United States | 4 | Completed | Pacira BioSciences | Apr 2015 | 12 |
| NCT02142829Obesity · United States | 4 | Completed | Pacira BioSciences | Mar 2013 | 101 |
| NCT02058290Intestinal Obstruction · United States | 4 | Terminated | Pacira BioSciences | Sep 2012 | 122 |
| NCT01919190Pain · United States | 4 | Terminated | Pacira BioSciences | Dec 2013 | 67 |
| NCT01919606Pain, Postoperative | 4 | Terminated | Pacira BioSciences | Oct 2012 | 1 |
| NCT01802411Pain, Postoperative · United States, Bulgaria, Czechia and more | 3 | Completed | Pacira BioSciences | Jun 2013 | 191 |
| NCT01801124Hernia · United States | 4 | Completed | Pacira BioSciences | Dec 2012 | 13 |
| NCT01683071Pain, Postoperative · United States | 3 | Completed | Pacira BioSciences | Dec 2013 | 297 |
| NCT01582477Pain, Postoperative · United States | 4 | Completed | Pacira BioSciences | May 2012 | 24 |
| NCT01509807Retraction of Colostomy · United States | 4 | Completed | Pacira BioSciences | Oct 2012 | 33 |
| NCT01509638Retraction of Colostomy · United States | 4 | Completed | Pacira BioSciences | Oct 2012 | 47 |
| NCT01507233Intestinal Obstruction · United States | 4 | Terminated | Pacira BioSciences | Jul 2012 | 5 |
| NCT01507246Intestinal Obstruction · United States | 4 | Completed | Pacira BioSciences | Jul 2012 | 42 |
How it is read
Names in the registry
- “EXPAREL”, 15 entries
- “bupivacaine liposome injectable suspension”, 4 entries
- “Exparel”, 3 entries
- “Exparel Injectable Product”, 2 entries
- “EXPAREL 266 mg”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 10 studies
- Pain, 7 studies
- Bunion, 3 studies
- Intestinal Obstruction, 3 studies
- Hallux Valgus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.